>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Dimethylcurcumin

Dimethylcurcumin ASC-J9; GO-Y025

Dimethylcurcumin (ASC-J9) 是一种雄激素受体降解增强剂，可有效抑制耐药性前列腺癌细胞增殖和侵袭。

货号：
TK0625
规格：

1mg

5mg

10mg
价格：
￥0.00

产品参数

CAS No.	52328-98-0
生物活性	Dimethylcurcumin (ASC-J9) is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.
分子式	C23H24O6
分子量	396.43
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : ≥ 50 mg/mL (126.13 mM)
体内研究	Dimethylcurcumin (ASC-J9) (75 mg/kg, i.p.) degrades both fAR and AR3 in the xenografted tumors in vivo, and SC-J9-treated tumors has significantly decreased Ki67-positive cells. Dimethylcurcumin (ASC-J9) (50 mg/kg every 48 h, i.p.) substantially ameliorates the SBMA symptoms in AR-97Q mice, and ameliorates neuromuscular pathological findings. The Dimethylcurcumin (ASC-J9)-treated SBMA mice have relatively normal serum testosterone concentrations. ASC-J9-treated mice show significantly smaller prostate tumor sizes when compared with those receiving classic ADT/castration with little serum androgen.
体外研究	Dimethylcurcumin (ASC-J9) is able to degrade fAR and AR3 in a dose-dependent manner in various human PCa cells. Dimethylcurcumin (ASC-J9) can also effectively suppress AR-targeted genes in CWR22Rv1-fARKD cells. Dimethylcurcumin (ASC-J9) (5 or 10 µM) significantly suppresses the DHT-induced cell growth in all three PCa cell lines. Dimethylcurcumin (ASC-J9) suppresses AR-targeted genes and cell growth by degradation of fAR and ectopic AR3 in C81 and C4-2 cells. Dimethylcurcumin (ASC-J9) selectively promotes AR degradation by disrupting the interaction between AR and AR coregulators. ASC-J9 reduces the AR aggregated AR-112Q in cells. Dimethylcurcumin (ASC-J9) suppresses the aggregation of AR-112Q in SBMA PC12/AR-112Q cells.
文献	•Mol Cancer Ther. 2016 Jul;15(7):1702-12. •Biochem Pharmacol. 2017 Sep 15;140:73-88. •Endocrinology. 2019 Apr 1;160(4):947-963. •J Steroid Biochem Mol Biol. 2021 May 11;105906. •Transl Oncol. 2021 May 13;14(8):101115. •J Ovarian Res. 2018 May 2;11(1):36. •Biochem Biophys Res Commun. 2018 Nov 17;506(1):130-136. •Biochem Biophys Res Commun. 2017 Apr 15;485(4):746-752. •Biol Sex Differ. 2020 Mar 29;11(1):12. •EXCLI J. 2019 Jan 24;18:21-29. •Oncotarget. 2016 Jun 14;7(24):36814-36828. •Tumour Biol. 2015 Nov;36(11):8727-33.
纯度及产品资料	98%

推荐产品